SecBot SecBot
SECBOTREPLAY Home › Report › SMMT

SMMT · Phase III HARMONi-10 initiated

Summit Therapeutics Inc. · 8-K filed Nov 18, 2026 at 08:16 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 18, 2026 at 08:16 ET

Summit Therapeutics announced the planned initiation of a global Phase III trial, HARMONi-10, evaluating ivonescimab versus durvalumab as consolidation therapy in unresectable Stage III non-small cell lung cancer. This is the company's sixth sponsored Phase III study of ivonescimab and expands its development program into the locally advanced, unresectable setting. No financial data or clinical results were disclosed.

  • Summit announced the planned initiation of the global Phase III HARMONi-10 trial of ivonescimab.
  • HARMONi-10 will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not progressed after platinum-based concurrent chemoradiation.
  • Global clinical trial site activations are expected to begin in Q4 2026.
  • HARMONi-10 is Summit's sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access